Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Pranav Murthy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4356-5170; OpenAlex author ID A5020618268. Sources: OpenAlex.

Their work

Papers
9 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 9

  1. Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Co-author DOI 10.1158/1078-0432.ccr-25-1110↗
  2. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2023.7070↗
  3. Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. First author DOI 10.1016/j.drudis.2021.09.011↗
  4. Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/cji.0000000000000370↗
  5. A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Co-author DOI 10.1158/1078-0432.ccr-19-4042↗
  6. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08094-0↗
  7. ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-08136-7↗
  8. The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. First author DOI 10.1007/s00277-019-03692-0↗
  9. Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. First author DOI 10.1186/s12885-018-4584-2↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael T. Lotze · 8 shared papers, 2018–2026 · strength 1.10
  2. Amer H. Zureikat · 5 shared papers, 2020–2026 · strength 0.75
  3. Brian A. Boone · 6 shared papers, 2018–2021 · strength 0.72
  4. Alessandro Paniccia · 3 shared papers, 2021–2026 · strength 0.55
  5. Aatur Dilip Singhi · 3 shared papers, 2020–2026 · strength 0.52
  6. Asmita Chopra · 2 shared papers, 2021–2026 · strength 0.38
  7. Nathan Bahary · 3 shared papers, 2020–2023 · strength 0.37
  8. Herbert J. Zeh · 4 shared papers, 2018–2020 · strength 0.37
  9. Renee R. Anderko · 1 shared paper, 2026 · strength 0.26
  10. Sebastiaan Ceuppens · 1 shared paper, 2026 · strength 0.26
  11. Jennifer Lee Miller-Ocuin · 3 shared papers, 2018–2020 · strength 0.25
  12. Jacob Cuyler · 1 shared paper, 2022 · strength 0.19
  13. Xiang‐Qun Xie · 1 shared paper, 2022 · strength 0.19
  14. Samer S. AlMasri · 1 shared paper, 2023 · strength 0.17
  15. Randall E. Brand · 1 shared paper, 2021 · strength 0.12
  16. Amr I. Al Abbas · 1 shared paper, 2020 · strength 0.11
  17. Caroline J. Rieser · 1 shared paper, 2020 · strength 0.11
  18. Sebastian Vogel · 1 shared paper, 2019 · strength 0.09
  19. Ravi K. Amaravadi · 1 shared paper, 2020 · strength 0.09
  20. Melissa Ellen Hogg · 1 shared paper, 2020 · strength 0.09
  21. Allan Tsung · 1 shared paper, 2020 · strength 0.09
  22. David L. Bartlett · 1 shared paper, 2020 · strength 0.09
  23. Daolin Tang · 1 shared paper, 2020 · strength 0.09
  24. Matthew D. Neal · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.